Abstract: A monoclonal antibody, or fragments thereof, having binding specificity for both endoglin expressed on human vascular endothelial cells and on murine endothelial cells. Antiangiogenic therapy in mammals can be effected by administering to the mammalian host a therapeutically effective amount of an anti-endoglin monoclonal antibody, or fragment thereof, which is conjugated to at least one angiogenesis inhibitor or antitumor agent. The composition is useful for treating tumor and angiogenesis-associated diseases.

Abstract: The invention provides recombinant antibody molecules comprising antigen binding regions derived from the heavy and/or light chain variable regions of a donor anti-CD3 antibody, e.g. OKT3, and which have anti-CD3 binding specificity, preferably of affinity similar to that of OKT3. The recombinant antibody is preferably a humanized antibody and may be a chimeric or CDR-grafted antibody. A method is disclosed for preparing CDR-grafted humanized antibodies in which, in addition to the CDR's, non-human antibody residues are preferably used at positions 23, 24, 49, 71, 73 and 78 of the heavy chain variable region and at positions 46, 48, 58, and 71 of the light chain variable region. The recombinant, especially the humanized, anti-CD3 antibodies may used for in vivo therapy or diagnosis.

Abstract: Binding of two members of a binding couple reveals epitopes which are revealed only after binding and the monoclonal antibody secreted from the hybridoma cell line CG-10 directed against these epitopes bind to the bound couple at a significantly higher affinity than their binding affinity to either of the two members themselves when not bound to one another.

Abstract: The invention provides assays for the presence or absence of CD4+ T cell subpopulations carrying particular V.beta. components of the T cell receptor (TCR-V.beta.) in persons infected with HIV, including amplification of mRNA from T cells with primers specific to each TCR-V.beta. to detect the presence or absence of each TCR-V.beta. in a sample and primers for use in such amplification assays are disclosed. The invention also provides assays of antibody-containing fluids of a person infected with HIV to determine the immunodeficiency where the fluid is suspected to contain an antibody having a paratope specific to an epitope on a TCR-V.beta.. The invention also provides a binding agent specific to a paratope where the paratope is specific to an epitope on a TCR-V.beta.. The invention also provides a method of assay of the fluids of a person infected with HIV to determine the immunodeficiency of the person which utilizes a binding agent specific to complexes containing anti-TCR-V.beta. antibody bound to TCR-V.

Abstract: This invention provides a CMP (Chemical-Mechanical Polishing) method for controlling the polishing rate using ionized water and a CMP apparatus which employs the CMP method. A polishing pad is attached to a polishing disc. A semiconductor wafer is held by a wafer carrier placed above the polishing disc, and is pressed by the wafer carrier against the polishing pad which rotates together with the polishing disc. As a result, the semiconductor wafer is polished. The polishing is performed while a polishing slurry containing polishing particles is supplied to the polishing pad from a polishing slurry tank through a polishing-slurry supply pipe, and ionized water is supplied thereto through an ionized-water supply pipe. In the case of using alkaline ionized water as the ionized water, the polishing rate can be increased in a stable manner by increasing the pH value of alkaline ionized water, and can be reduced in a stable manner by reducing the pH value of alkaline ionized water.

Abstract: A method using compounds inhibiting binding reactions involving GMP-140 to modulate an inflammatory response. The method is based on the discovery that GMP-140, released from the storage granules of platelets, endothelial cells, and megakaryocytes, and redistributed to the surface of the cells within seconds of activation by mediators such as thrombin, ionophores or histamine, binds to a ligand on neutrophils, and the plasma proteins C3b and protein S. Adhesion of the cells following activation is blocked directly by administration of antibody to GMP-140 or its ligand, or by competitive inhibition by administration of soluble GMP-140, the GMP-140 ligand, or the specific carbohydrate portion of the ligand bound by GMP-140.

Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.

Abstract: The present invention provides DNA sequences encoding complementarity determining regions of variable domains of human anti-RhD antibodies and their use in the production of recombinant chimeric antibody molecules. Chimeric antibody molecules against the Rhesus (D) antigen or an antigen binding fragment thereof, as well as anti-Rhesus (D) reagents and pharmaceutical compositions comprising said chimeric antibodies are also provided.

Abstract: Disclosed is a solid cosmetic composition (e.g., a cream composition) containing an active cosmetic material (e.g., a deodorant active, an antiperspirant active, a sunscreen, an insect repellent and/or an anti-fungal agent) and a silicone gel material. The silicone gel material includes (a) a volatile silicone material and (b) an organopolysiloxane material as a gelling agent, able to form a gel after being mixed with the volatile silicone material. The organopolysiloxane material can be a reaction product of a vinyl-terminated siloxane polymer and a hydride cross-linking agent. The composition can be formed by mixing the active cosmetic material and silicone gel material at ambient temperature. The compositions do not need particulate or clay thickeners or waxy gelling agents.

Abstract: Immunoconjugates comprising the monoclonal antibody TXU-5/B53 linked to pokeweed antiviral protein or bioactive subunits thereof are provided which are effective for the treatment of mammalian HIV infection.

Abstract: Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.

Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

Abstract: A low profile, two-piece ostomy appliance is disclosed that has a contact responsive non-tacky fastener system comprising a fastener that is attached to the ostomy appliance and a landing zone component that is attached to the peristomal area of the user. The fastening layer of the fastener system is preferably multiply releasable and refastenable against the non-tacky target, and preferably has a 90.degree. peel strength of less than about 3 kN/m and a dynamic shear strength of greater than 2 kN/m.sup.2 when in contact with the target surface.

Abstract: The present invention comprises the method of selectively suppressing an immune response of a mammal to a particular alloantigen. The method includes several steps. One step is administering to a mammal an effective amount of UVB-radiation. It is demonstrated herein UVB radiation selectively suppresses the DTH response in mammals. Epidermal cell cultures, when subjected to UVB irradiation (280 nm to 320 nm) produce a specific immunosuppressive factor. The immunosuppressive factor is reactive with an antibody directed toward IL-10. Another step of the inventive method involves desensitizing a mammal to a particular alloantigen. It has been determined that a mammal will become tolerant to a particular alloantigen once the subject mammal has been irradiated with a pre-determined wavelength of UVR and thereafter sensitized with the particular alloantigen. This may analogously be accomplished using the immunosuppressive factor from in vitro epidermal cell cultures of the present invention.

Abstract: A process for enriching substance emissions released from an object in the form of gases, vapors or aerosols, wherein the substance emissions are fed to an adsorption layer by diffusion or penetration and are enriched in the adsorption layer. The substance emission of an object is selectively detected according to the present invention by the adsorption layer being fixed on the surface of the object emitting pollutant, which surface is to be analyzed, by means of an adhesive tape projecting over the adsorption layer on all sides to offer adhesive surfaces for application to the object and to hermetically seal the adsorption layer against the ambient air. A nondestructive adsorption system is also provided, with direct or immediately following analysis for the rapid qualitative and/or quantitative determination of pollutants (e.g., gases, vapors, dusts) by means of a chemical or biological reaction, in which, e.g.

Abstract: A freeze-dried monoclonal antibody preparation is prepared by adding to a solution of the monoclonal antibody gelatin or carboxylic acid or its salt, to prevent denaturation of the monoclonal antibodies during freeze-drying. Freeze-dried monoclonal antibody preparations having stablized antigen-binding activity result and may be used as an adminiculum for immunoauxotherapy for prophylaxis and treatment of bacterial infectious diseases and viral infectious diseases.

Abstract: An improved area monitor for detecting gas concentration is provided that requires a very infrequent calibration, and works reliably in detecting a particular target gas using only two semiconductor sensors. One of these sensors will exhibit a drift that is constantly monitored and automatically compensated for, while the other sensor exhibits a stable, repeatable response over very long periods of time. Once the "stable" has been initially calibrated, the concentration of the target gas can be discerned directly from the resistance of this sensor, although more that one particular chemical gas may cause the stable sensor to change resistance. The second sensor is then used to discern whether or not the change in resistance of the stable sensor was due to the actual target chemical, or due to some other similar chemical. The second sensor is selected to be of a type that responds in one direction (i.e.

Abstract: Monoclonal antibodies which bind mevalonate kinase, hybrid cell lines which produce these monoclonal antibodies, and immunoassay methods for detecting mevalonate kinase using these monoclonal antibodies.